Daiichinkyo Co (TSE:4568) Short-Term Debt & Capital Lease Obligation : 円399 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円399 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Daiichinkyo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円101,314 Mil.

Daiichinkyo Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Short-Term Debt & Capital Lease Obligation Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

40,389.00

20,391.00

20,394.00

41,396.00

399.00

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															41,396.00	55,457.00	12,871.00	12,819.00	399.00

Daiichinkyo Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Daiichinkyo Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (TSE:4568) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines